Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

U.S. Stem Cell

OTCPK:USRM
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
USRM
OTCPK
$4M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. The last earnings update was 151 days ago. More info.


Add to Portfolio Compare Print
  • U.S. Stem Cell has significant price volatility in the past 3 months.
USRM Share Price and Events
7 Day Returns
81.8%
OTCPK:USRM
2%
US Biotechs
-2.8%
US Market
1 Year Returns
-52.4%
OTCPK:USRM
-1.3%
US Biotechs
-15.9%
US Market
USRM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
U.S. Stem Cell (USRM) 81.8% 47.1% 170.3% -52.4% -91.6% -99.9%
US Biotechs 2% -8% -4.6% -1.3% 10.5% -12%
US Market -2.8% -18.8% -24% -15.9% 2.8% 13.3%
1 Year Return vs Industry and Market
  • USRM underperformed the Biotechs industry which returned -1.3% over the past year.
  • USRM underperformed the Market in United States of America which returned -15.9% over the past year.
Price Volatility
USRM
Industry
5yr Volatility vs Market
Related Companies

Value

 Is U.S. Stem Cell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether U.S. Stem Cell is trading at an attractive price based on the cash flow it is expected to produce in the future. But as U.S. Stem Cell has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for U.S. Stem Cell. This is due to cash flow or dividend data being unavailable. The share price is $0.01.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for U.S. Stem Cell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are U.S. Stem Cell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:USRM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.01
OTCPK:USRM Share Price ** OTCPK (2020-04-03) in USD $0.01
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.72x
United States of America Market PE Ratio Median Figure of 2,947 Publicly-Listed Companies 12.21x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of U.S. Stem Cell.

OTCPK:USRM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:USRM Share Price ÷ EPS (both in USD)

= 0.01 ÷ -0.01

-1.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • U.S. Stem Cell is loss making, we can't compare its value to the US Biotechs industry average.
  • U.S. Stem Cell is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does U.S. Stem Cell's expected growth come at a high price?
Raw Data
OTCPK:USRM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.8x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.88x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for U.S. Stem Cell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on U.S. Stem Cell's assets?
Raw Data
OTCPK:USRM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.02
OTCPK:USRM Share Price * OTCPK (2020-04-03) in USD $0.01
United States of America Biotechs Industry PB Ratio Median Figure of 430 Publicly-Listed Biotechs Companies 2.46x
United States of America Market PB Ratio Median Figure of 5,146 Publicly-Listed Companies 1.2x
OTCPK:USRM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:USRM Share Price ÷ Book Value per Share (both in USD)

= 0.01 ÷ -0.02

-0.44x

* Primary Listing of U.S. Stem Cell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • U.S. Stem Cell has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of USRM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess U.S. Stem Cell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. U.S. Stem Cell has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is U.S. Stem Cell expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as U.S. Stem Cell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is U.S. Stem Cell expected to grow at an attractive rate?
  • Unable to compare U.S. Stem Cell's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare U.S. Stem Cell's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare U.S. Stem Cell's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:USRM Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:USRM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:USRM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 4 -1 -4
2019-06-30 6 -1 -2
2019-03-31 6 0 -3
2018-12-31 7 1 -2
2018-09-30 7 1 -1
2018-06-30 7 1 -2
2018-03-31 6 2 -1
2017-12-31 6 1 -3
2017-09-30 5 1 -4
2017-06-30 4 1 -4
2017-03-31 4 0 -4
2016-12-31 3 0 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if U.S. Stem Cell is high growth as no earnings estimate data is available.
  • Unable to determine if U.S. Stem Cell is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:USRM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from U.S. Stem Cell Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:USRM Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 0.00
2018-06-30 -0.01
2018-03-31 0.00
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.03
2017-03-31 -0.05
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if U.S. Stem Cell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of USRM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. U.S. Stem Cell's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access U.S. Stem Cell's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess U.S. Stem Cell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
U.S. Stem Cell has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has U.S. Stem Cell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare U.S. Stem Cell's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • U.S. Stem Cell does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare U.S. Stem Cell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare U.S. Stem Cell's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
U.S. Stem Cell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from U.S. Stem Cell Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:USRM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 4.43 -3.60 4.84 0.00
2019-06-30 5.77 -2.29 4.40 0.00
2019-03-31 6.30 -2.69 5.65 0.00
2018-12-31 6.70 -2.16 5.68 0.01
2018-09-30 6.51 -1.37 5.26 0.00
2018-06-30 6.51 -1.97 6.10 0.00
2018-03-31 6.08 -1.15 4.81 0.01
2017-12-31 5.52 -3.48 4.43 0.01
2017-09-30 5.01 -3.50 4.23 0.00
2017-06-30 4.23 -4.25 3.62 0.00
2017-03-31 3.53 -4.18 3.53 0.00
2016-12-31 3.08 -2.07 3.26 0.00
2016-09-30 2.70 -3.76 4.15 -0.02
2016-06-30 2.53 -2.20 3.23 0.01
2016-03-31 2.41 -0.96 3.31 0.01
2015-12-31 2.19 -1.64 3.75 0.01
2015-09-30 2.10 -1.29 3.66 0.07
2015-06-30 2.14 -2.64 4.78 0.05
2015-03-31 2.15 -3.98 4.83 0.06
2014-12-31 2.06 -2.25 4.67 0.07
2014-09-30 1.60 -1.97 3.81 0.17
2014-06-30 1.04 -1.65 3.13 0.32
2014-03-31 0.48 -1.95 2.74 0.47
2013-12-31 0.10 -3.14 2.27 0.63
2013-09-30 0.07 -3.62 2.36 0.60
2013-06-30 0.04 -3.58 2.09 0.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if U.S. Stem Cell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if U.S. Stem Cell has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if U.S. Stem Cell improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess U.S. Stem Cell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
U.S. Stem Cell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is U.S. Stem Cell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up U.S. Stem Cell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • U.S. Stem Cell's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • U.S. Stem Cell's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of U.S. Stem Cell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • U.S. Stem Cell has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from U.S. Stem Cell Company Filings, last reported 6 months ago.

OTCPK:USRM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -9.11 6.18 0.08
2019-06-30 -7.68 5.33 0.59
2019-03-31 -7.10 4.76 0.75
2018-12-31 -6.88 5.02 1.36
2018-09-30 -7.04 5.11 1.45
2018-06-30 -7.04 5.26 1.67
2018-03-31 -6.40 4.44 1.72
2017-12-31 -7.10 4.80 0.99
2017-09-30 -7.54 5.12 0.96
2017-06-30 -7.14 4.27 0.93
2017-03-31 -7.52 5.26 0.62
2016-12-31 -8.02 5.29 0.27
2016-09-30 -8.74 5.48 0.25
2016-06-30 -7.63 4.64 0.13
2016-03-31 -7.69 4.73 0.28
2015-12-31 -7.72 4.65 0.06
2015-09-30 -8.72 5.39 0.07
2015-06-30 -9.16 5.32 0.09
2015-03-31 -10.88 5.47 0.07
2014-12-31 -10.89 5.41 0.04
2014-09-30 -10.81 5.36 0.05
2014-06-30 -10.41 4.55 0.09
2014-03-31 -12.17 5.65 0.22
2013-12-31 -13.75 5.67 0.05
2013-09-30 -13.65 5.72 0.01
2013-06-30 -13.81 6.11 0.17
  • U.S. Stem Cell has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if U.S. Stem Cell's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • U.S. Stem Cell has less than a year of cash runway based on current free cash flow.
  • U.S. Stem Cell has less than a year of cash runway if free cash flow continues to reduce at historical rates of -41.1% each year.
X
Financial health checks
We assess U.S. Stem Cell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. U.S. Stem Cell has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is U.S. Stem Cell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from U.S. Stem Cell dividends.
If you bought $2,000 of U.S. Stem Cell shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate U.S. Stem Cell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate U.S. Stem Cell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:USRM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 66 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1936 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2.1%
United States of America Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as U.S. Stem Cell has not reported any payouts.
  • Unable to verify if U.S. Stem Cell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of U.S. Stem Cell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as U.S. Stem Cell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess U.S. Stem Cell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can U.S. Stem Cell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. U.S. Stem Cell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of U.S. Stem Cell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Tomas
COMPENSATION $2,797,439
AGE 53
TENURE AS CEO 9.8 years
CEO Bio

Mr. Michael Tomas, also known as Mike, has been the Chief Executive Officer and President of U.S. Stem Cell, Inc. since June 18, 2010. Mr. Tomas serves as the Vice President of Corporate Affairs of Pharmed Group. He serves as Chief Financial Officer at U.S. Stem Cell, Inc. He spent nearly 20 years driving the evolution of telecommunications technology in the U.S. and Mexico in leadership roles ranging from sales, marketing, customer service, telemarketing, engineering, and operations. He serves as the Chief Strategic Officer of Total Home Health Inc. He serves as the Chairman of Eugenio Pino & Family Global Entrepreneurship Center at Florida International University. Mr. Tomas has been the President at The Astri Group for nine years. He served as the President of Apex Capital from June 2000 to January 2001. From 1984 to June 2000, he served as the Chief Marketing Officer at Avantel-MCI and Axtel S. A. B. De CV. After Avantel-MCI, he served as Vice President and General Manager of Ineto International. He also served as the Chief Executive Officer of The Edwards Group. He started his business career with MCI. After 17 years with MCI, he joined WorldCom. Mr. Tomas joined other retired MCI executives and helped raise $40 million in venture capital to form Ineto. Mr. Tomas sits on the boards of Rokk3r Labs, The IDEA Center, Career Source Florida. He serves as a Director at Living Independently Group, Inc., BAE Systems Applied Intelligence US Corp. and Total Home Health Inc. He serves as a Member of Board of Advisors at JustAskBoo, LLC. He has been a Director of U.S. Stem Cell, Inc. since June 19, 2010 and served as its Member of the Advisory Board from February 2012 to November 24, 2015. Mr. Tomas has been a Director of Easy Solutions Inc., since July 10, 2013 and Workforce Florida, Inc. since August 14, 2013. He served as a Director of U.S. Stem Cell, Inc. from April 2003 to November 20, 2008. He served as a Director of Avisena, Inc. Mr. Tomas is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner--and winner of top communications, medical innovations, education and entrepreneurial awards. An avid athlete, Mr. Tomas was also a Miami-Dade County Sports Commissioner. He is a Founding Coach and Mentor at the University of Miami's Launch Pad entrepreneurship program at the Toppel Center. He was named a 2012 Hall of Famer by Miami Dade College. He holds an M.B.A. from the University of Miami in 2000 and a B.A. in Industrial Organizational Psychology from Florida International University in 1990. Mr. Tomas also holds an Associates degree from Miami Dade College.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the U.S. Stem Cell management team in years:

6.9
Average Tenure
  • The average tenure for the U.S. Stem Cell management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike Tomas

TITLE
CEO, President
COMPENSATION
$3M
AGE
53
TENURE
9.8 yrs

Colleen Robb

TITLE
Senior Compliance Officer
TENURE
6.6 yrs

Phil Posa

TITLE
Senior Vice President of U.S. & International Sales
TENURE
1.6 yrs

Evelyn Flores

TITLE
Corporate Controller
TENURE
6.9 yrs

Sergio Pinski

TITLE
Medical Director & Member of Scientific Advisory Board
TENURE
15.3 yrs

Jim Greene

TITLE
Clinical Operations Consultant

Fabianne Gershon

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the U.S. Stem Cell board of directors in years:

9.6
Average Tenure
71
Average Age
  • The tenure for the U.S. Stem Cell board of directors is about average.
Board of Directors

William Murphy

TITLE
Chairman
COMPENSATION
$33K
AGE
95
TENURE
9.4 yrs

Mike Tomas

TITLE
CEO, President
COMPENSATION
$3M
AGE
53
TENURE
9.8 yrs

Sergio Pinski

TITLE
Medical Director & Member of Scientific Advisory Board

Mark Borman

TITLE
Director
COMPENSATION
$33K
AGE
64
TENURE
2.3 yrs

Doris Taylor

TITLE
Member of Scientific Advisory Board

Miranda Grounds

TITLE
Member of Scientific Advisory Board

Jorge Genovese

TITLE
Member of Scientific Advisory Board
TENURE
13.3 yrs

Syde Taheri

TITLE
Member of Scientific Advisory Board

Marc Penn

TITLE
Member of Scientific Advisory Board

Robert A. Tassel

TITLE
Member of Scientific Advisory Board
AGE
78
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess U.S. Stem Cell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. U.S. Stem Cell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company’s product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.

Details
Name: U.S. Stem Cell, Inc.
USRM
Exchange: OTCPK
Founded: 1999
$4,249,355
424,935,588
Website: http://www.us-stemcell.com
Address: U.S. Stem Cell, Inc.
1560 Sawgrass Corporate Parkway,
4th Floor,
Sunrise,
Florida, 33323,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK USRM Common Stock Pink Sheets LLC US USD 19. Feb 2008
Number of employees
Current staff
Staff numbers
11
U.S. Stem Cell employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 03:40
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2019/11/06
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.